Faricimab CAS 1607793-29-2

Identification

CAS Number

1607793-29-2

Name

Faricimab

Properties

Safety Data

Symbol

Signal Word

Warning

WGK Germany

3

MSDS Download

Specifications and Other Information of Our

Identification Methods

HNMR, HPLC

Known Application

Faricimab is a bispecific antibody that is promising for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It simultaneously targets and blocks two key pathogenic pathways – angiopoietin-2 (Ang). -2) and vascular endothelial growth factor-A (VEGF-A), two pathways that drive many retinal diseases that lead to vision loss by destabilizing blood vessels.

General View of Documents

This product is developed by our R&D company Watson Bio Limited (https://www.watson-bio.com/).

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).